Breaking News Instant updates and real-time market news.

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

, UTX

United Technologies

$111.23

-2.7 (-2.37%)

20:25
01/22/19
01/22
20:25
01/22/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Procter & Gamble (PG), consensus $1.21... Comcast (CMCSA), consensus 62c... Abbott Laboratories (ABT), consensus 81c... United Technologies (UTX), consensus $1.53... Kimberly-Clark (KMB), consensus $1.65... Progressive (PGR), consensus $1.01... Amphenol (APH), consensus 98c... Synchrony Financial (SYF), consensus 92c... Waters (WAT), consensus $2.65.

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

UTX

United Technologies

$111.23

-2.7 (-2.37%)

ABT

Abbott

$71.56

0.13 (0.18%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

PG

Procter & Gamble

$90.50

-0.89 (-0.97%)

PGR

Progressive

$63.18

-1.24 (-1.92%)

APH

Amphenol

$81.06

-1.41 (-1.71%)

SYF

Synchrony

$26.55

0.27 (1.03%)

WAT

Waters

$203.52

-3.315 (-1.60%)

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 27

    Jan

  • 30

    Jan

  • 11

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

KMB Kimberly-Clark
$115.15

-1.675 (-1.43%)

01/18/19
JPMS
01/18/19
UPGRADE
Target $129
JPMS
Overweight
Kimberly-Clark upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Kimberly-Clark (KMB) to Overweight and raised her price target for the shares to $129 from $108. While the company's sales growth is still facing secular challenges, it has an opportunity to drive "significant operating margin expansion ahead," Teixeira tells investors in a research note. Following two consecutive years of operating margin challenges, the analyst believes Kimberly-Clark's margins can inflect positively in 2019 due to cost savings, price increases and waning input cost inflation. Teixeira's top pick in Household and Personal Care remains Procter & Gamble (PG).
10/17/18
WELS
10/17/18
NO CHANGE
Target $105
WELS
Market Perform
Kimberly-Clark price target raised to $105 from $97 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Kimberly-Clark to $105 from $97 ahead of quarterly results. The analyst reiterates a Market Perform rating on the shares.
10/10/18
10/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MCDONALD'S UPGRADED TO BUY: Guggenheim analyst Matthew DiFrisco upgraded McDonald's (MCD) to Buy from Neutral with a $200 price target as he believes the shares valuation discount to large cap peers has widened to an "unjustifiable" level given his outlook for stable to improving same-store sales and greater free cash flow generation. DEUTSCHE CUTS CONSUMER STAPLES STOCKS TO SELL: Deutsche Bank analyst Steve Powers downgraded Clorox (CLX), Church & Dwight (CHD) and Kimberly-Clark (KMB) to Sell from Hold and lowered his price targets to $123, $51, and $99, respectively. While investor appetite for defensive names remains elevated, the fundamental challenges facing Consumer Packaged Goods companies are "somewhat underappreciated," Powers believes. The analyst believes currency and emerging market volatility will pressure numbers in the near-term, while structural competitive and retail pressures will challenge momentum longer-term. PIPER STARTS MICRON AT NEUTRAL: Piper Jaffray analyst Harsh Kumar initiated coverage of Micron Technology (MU) with a Neutral rating and $48 price target. The analyst awaits more clarity surrounding the mid-term dynamics of the memory cycle before getting more constructive on the shares. The memory market as a whole has experienced favorable trends over the last few years, Kumar said. However, given the cyclical nature of the memory market, the analyst prefers to remain on the sidelines until he has a better grasp of the cycle. JPMORGAN ADDS DROPBOX TO FOCUS LIST: JPMorgan analyst Mark Murphy added Dropbox (DBX) to his firm's Analyst Focus List while keeping an Overweight rating on the shares with a $35 price target. While not convinced the "seven-day-old growth tech selloff is over," the analyst sees an improving risk/reward on Dropbox shares and potential for 30%-50% outperformance. He believes investors are "underestimating the stability and consistency of the Dropbox engine," and are overlooking the launch and adoption of its Premium plans. JPMORGAN SAYS GE TURBINE ISSUES MAY BE WORSE THAN THOUGHT: Recently published feedback from a General Electric (GE) H-frame user group event suggests more serious technology issues with the new flagship product, JPMorgan analyst Stephen Tusa said. While most of the focus has been on the technology around the blades, the event indicates a "myriad of shortfalls in other parts of the turbine that we find hard not to consider 'technology flaws,'" Tusa said. Tusa kept an Underweight rating on shares of General Electric.
10/10/18
10/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Vipshop (VIPS) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao saying as the "tough competitive environment and harder-than-expected synergy generation," Vipshop is likely to adjust its strategy to re-focus on core off-season apparel distribution and prioritize profitability over sales growth. 2. International Paper (IP) downgraded to Neutral from Buy at Goldman Sachs while WestRock (WRK) was downgraded to Buy from Conviction Buy. 3. Clorox (CLX), Church & Dwight (CHD), and Kimberly-Clark (KMB) were downgraded to Sell from Hold at Deutsche Bank. 4. Sherwin-Williams (SHW) downgraded to Neutral from Buy at Citi with analyst P.J. Juvekar saying "tough" market comments from companies like H.B. Fuller (FUL), PPG (PPG) and RPM (RPL) suggest that coatings companies are likely to be challenged by rising raw materials costs and slowing growth in key end markets, including China. 5. KKR (KKR) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
UTX United Technologies
$111.23

-2.7 (-2.37%)

01/03/19
SBSH
01/03/19
INITIATION
Target $120
SBSH
Neutral
United Technologies resumed with a Neutral at Citi
Citi analyst Jonathan Raviv resumed coverage of United Technologies with a Neutral rating and lowered his price target for the shares to $120 from $125. The biggest catalyst came in late November when the company announced the closure of the Rockwell Collins acquisition and the planned three-way split between Aero, Otis and Carrier, Raviv tells investors in a research note. The analyst says the next big catalyst isn't for another 18-24 months when the split becomes official.
01/03/19
RBCM
01/03/19
DOWNGRADE
Target $119
RBCM
Sector Perform
United Technologies downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Deane Dray downgraded United Technologies to Sector Perform from Outperform and lowered his price target to $119 from $139.
01/04/19
RBCM
01/04/19
DOWNGRADE
Target $119
RBCM
Sector Perform
United Technologies downgraded to Sector Perform from Outperform at RBC Capital
As noted earlier, RBC Capital analyst Deane Dray downgraded United Technologies to Sector Perform from Outperform and lowered his price target to $119 from $139. The analyst believes that shares are likely "stuck in limbo" until the mid-late 2020 spin transactions, adding that the potential upside from the possible Carrier is not enough to keep him positive. Dray further warns about the "potential for some spin-related business disruptions and market share losses during this limbo period."
01/18/19
OTRG
01/18/19
DOWNGRADE
OTRG
Mixed
United Technologies downgraded to Mixed from Positive at OTR Global
OTR Global downgraded US Commercial HVAC Equipment Businesses for United Technologies (UTX), Johnson Controls (JCI), and Ingersoll-Rand (IR) to Mixed from Positive. The firm's checks indicate softer demand and moderating quote activity over the past 90 days driven by seasonal weakness, and economic and political uncertainties.
ABT Abbott
$71.56

0.13 (0.18%)

01/02/19
SBSH
01/02/19
DOWNGRADE
Target $68
SBSH
Sell
Abbott downgraded to Sell from Neutral at Citi
Citi analyst Amit Hazan downgraded Abbott Laboratories to Sell and lowered his price target for the shares to $68 from $72.
12/17/18
FBCO
12/17/18
INITIATION
Target $82
FBCO
Outperform
Abbott initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic initiated Abbott with an Outperform rating and a price target of $82 as part of his broader research note on Medical Supplies and Devices partially titled "No Disruption, No Alpha", saying the stock offers "best exposure" to Diabetes medicine. The analyst contends that Abbott is "firing on all cylinders" with improving organic growth, sales mix, and investor returns, having produced organic revenue growth of about 8% over the last 4 quarters.
12/17/18
FBCO
12/17/18
INITIATION
Target $82
FBCO
Outperform
Abbott initiated with an Outperform at Credit Suisse
Credit Suisse initiated Abbott with an Outperform and $82 price target.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
CMCSK Comcast
$0.00

(0.00%)

10/26/18
10/26/18
UPGRADE
Target $44

Outperform
Credit Suisse upgrades Comcast to Outperform on increased confidence in growth
As previously reported, Credit Suisse analyst Douglas Mitchelson upgraded Comcast to Outperform from Neutral, stating that he has increased confidence in its growth outlook given renewed momentum in broadband net adds, pricing upside, the deteriorating competitive positioning of satellite, wireless investment likely having peaked, and NBCU being well positioned. Additionally, he sees the potential for capital intensity to moderate meaningfully over time. Mitchelson increased his estimates above consensus and raised his price target on Comcast shares to $44 from $36.
10/30/18
MSCO
10/30/18
NO CHANGE
Target $95
MSCO
Overweight
WWE shares 'on sale' after pullback, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that WWE (WWE) shares are down by over 30% this month, which he sees as a "rare opportunity" to buy shares of a company that he sees having both highly visible earnings growth and growing intellectual property value. He attributes the rapid selloff primarily to a broader market rotation out of risk assets due to rising interest rates and concerns over achieving long-term growth, but he thinks this "does not make sense" given that WWE's EBITDA opportunity "is not a decade away, but rather a year away," Swinburne tells investors. Two contracts underwritten by Comcast (CMCSA) and Fox (FOXA) drive the bulk of its earnings growth and its financial outlook has no immediate exposure to ratings or cord-cutting, Swinburne added. While he trimmed his price target on WWE shares to $95 from $105 after bumping up his investment expectations for 2019, the analyst maintains an Overweight rating on the stock.
11/08/18
MSCO
11/08/18
INITIATION
Target $46
MSCO
Overweight
Comcast resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage of Comcast (CMCSA) with an Overweight rating and $46 price target, stating that while the burden of proof is on the company to successfully execute its Sky (SKYAY) acquisition, the stock's multiple has compressed even though his expectation for Comcast's consolidated growth outlook has not materially changed. In the near-term, Sky will be accretive to that growth rate, Swinburne added. He also said that Comcast "remains first and foremost a US cable business," and he sees broadband as a secular growth driver with a long-term runway.
12/07/18
WOLF
12/07/18
INITIATION
Target $48
WOLF
Outperform
Comcast Comcast initiated with an Outperform at Wolfe Research
Wolfe Research initiated Comcast with an Outperform rating and $48 price target.
CMCSA Comcast
$35.16

-1.05 (-2.90%)

11/08/18
11/08/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) initiated with a Hold at Deutsche Bank. 2. Comcast (CMCSA) resumed with an Overweight at Morgan Stanley while Amarin (AMRN) and Immunomedics (IMMU) were assumed with a Buy at the firm. 3. Broadcom (AVGO) resumed with a Buy at Deutsche Bank and reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/18
LEHM
11/13/18
INITIATION
Target $44
LEHM
Overweight
Comcast reinstated with an Overweight at Barclays
Barclays analyst Kannan Venkateshwar reinstated coverage of Comcast with an Overweight rating and $44 price target. Negativity around the Sky deal seems overstated, Venkateshwar tells investors in a research note. There is "little doubt" that Comcast overpaid for Sky using any conventional valuation metric, says the analyst. However, he also believes looking at transaction multiples "essentially assumes a static strategic state for the combination, which is unlikely." The analyst thinks Comcast's guidance on synergies is likely to prove conservative.
12/03/18
JPMS
12/03/18
DOWNGRADE
Target $62
JPMS
Neutral
JPMorgan downgrades Verizon to Neutral after 17% rally, prefers AT&T
JPMorgan analyst Philip Cusick downgraded Verizon Communications (VZ) to Neutral from Overweight with an unchanged price target of $62. The analyst says that as much as he likes Verizon's "consistent and improving execution," the combination of a new management team and reporting lines with the stock's 17% year-to-date increase make the risk/reward less compelling than peers AT&T (T) and Comcast (CMCSA). Cusick, however, still sees the stock increasing 2.7% to his $62 target in the next year along with the 4.0% dividend yield.
PG Procter & Gamble
$90.50

-0.89 (-0.97%)

12/14/18
12/14/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dollar Tree (DLTR) upgraded to Outperform from Market Perform at Bernstein with analyst Brandon Fletcher saying while he still wants to see activism, he thinks management has done "enough" at the current valuation to make the grade. 2. Lattice Semiconductor (LSCC) upgraded to Outperform from Neutral at Baird with analyst Tristan Gerra saying Lattice has a highly defensible business model, in need of improved execution. 3. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the upgrade is based on "broad-based market share momentum, an improving gross margin outlook, and greater earnings achievability are not adequately reflected in relative valuation vs. peers." 4. Regeneron (REGN) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying he sees 25% upside after boosting his price target for the shares to $472 from $415. 5. Bausch Health (BHC) upgraded to Buy from Neutral at H.C. Wainwright analyst Raghuram Selvaraju saying now is an "appropriate time to become more bullish on the story." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
01/10/19
01/10/19
INITIATION

Outperform
Procter & Gamble initiated with an Outperform at Evercore ISI
Evercore ISI started Procter & Gamble with an Outperform rating and $105 price target.
PGR Progressive
$63.18

-1.24 (-1.92%)

12/20/18
FBCO
12/20/18
NO CHANGE
Target $74
FBCO
Outperform
Progressive price target lowered to $74 from $79 at Credit Suisse
Credit Suisse analyst Michael Zaremski lowered his price target for Progressive to $74 from $79 as he believes some investors are currently unwilling to buy into auto stocks as auto pricing falls. The analyst reiterates an Outperform rating on the shares.
01/08/19
GSCO
01/08/19
UPGRADE
Target $179
GSCO
Buy
Willis Towers Watson upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Yaron Kinar upgraded Willis Towers Watson (WTW) to Buy and raised his price target for the shares to $179 from $163. The analyst expects the impact of the company's restructuring and efficiency initiatives "to be more pronounced in 2019." He also sees Willis Towers' EBITDA margin improvement in 2019 being above peer average. The negative spread between the company's free cash flow margins and peers' should "meaningfully compress" in 2019, Kinar tells investors in a research note. Progressive (PGR) remains the analyst's top pick into 2019 in the Property & Casualty space.
01/09/19
LEHM
01/09/19
UPGRADE
Target $73
LEHM
Overweight
Progressive upgraded to Overweight from Underweight at Barclays
Barclays analyst Jay Gelb double upgraded Progressive to Overweight from Underweight and raised his price target for the shares to $73 from $67.
01/09/19
LEHM
01/09/19
NO CHANGE
LEHM
Barclays upgrades three P&C Insurers, downgrades RenaissanceRe
Barclays analyst Jay Gelb upgraded Travelers (TRV), Arch Capital Group (ACGL) and Progressive (PGR) to Overweight while downgrading RenaissanceRe to Underweight from Equal Weight. Travelers, Arch and Progressive are among the best managed companies in the Property and Casualty Insurance sector with "sustainably robust earning power, strong balance sheets, and increasingly attractive valuations," Gelb tells investors in a research note. He believes the recent share pullbacks have provided an attractive opportunity. And although he also views RenaissanceRe as well managed company, he thinks the stock's valuation is full and that reinsurance market conditions are unlikely to tighten.
APH Amphenol
$81.06

-1.41 (-1.71%)

10/16/18
MSCO
10/16/18
NO CHANGE
MSCO
Semi fundamentals look worse today than in 2015 down cycle, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach noted that the selloff in semiconductor stocks has been "swift and painful" and could be getting overdone near-term, though he worries the group is "by no means out of the woods" given his view that semi fundamentals today are worse than they were in the 2015 down cycle. Specifically, Hettenbach points to the degree of excess that built up in the supply chain this time, stating that the increase in lead times, double ordering, and inventory accumulation is markedly different to the period that preceded the last time there were broad-based semi estimate cuts in the second half of 2015. Semi sector estimates have only just recently started to come down and there are growing investor expectations that companies will guide Q4 revenue at least a few percent below the Street, added Hettenbach, who said the "upcoming earnings season will be the big test."
01/03/19
MSCO
01/03/19
NO CHANGE
MSCO
Skyworks, Qorvo among semi names with most Apple exposure, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach maintains his Cautious view on the Semiconductors sector, telling investors that the sizeable iPhone miss in China and a weaker China PMI reading this week provide further evidence of a strong downward bias in "the most important growth region for semis." He sees more reasons for investors to reduce exposure to semis, rather than add, ahead of what he expects to be a challenging earnings season, Hettenbach noted. In terms of exposure to Apple (AAPL), he estimates Skyworks (SWKS) has 45% exposure, followed by Qorvo (QRVO) at about 35% and Broadcom (AVGO) at 15%- 20%. Beyond the companies with the greatest Apple exposure, Hettenbach also highlight risks to broad-based suppliers such as Texas Instruments (TXN), Amphenol (APH), ON Semiconductor (ON), NXP Semiconductors (NXPI), Analog Devices (ADI) and Cypress Semiconductor (CY), calling out ON as his top Underweight idea.
10/09/18
10/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the retailer is reaping returns on the many years of investment in e-commerce and customer service. 2. Cree (CREE) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster saying he sees a more balanced risk/reward following the recent underperformance of the shares. 3. Amphenol (APH) upgraded to Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying the company's "best in class" execution and "diverse" end markets position it well in a tougher cyclical environment. 4. Dominion (D) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company is entering a period of balance sheet improvement, de-risked business mix and overall simplification, with or without the Scana (SCG) assets. 5. Baker Hughes (BHGE) upgraded to Buy from Hold at Jefferies with analyst Brad Handler saying earnings power of $4 per share next decade "seems tangible," as is free cash flow conversion of greater than 90% of estimated earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
GSCO
10/09/18
UPGRADE
Target $108
GSCO
Buy
Amphenol upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Mark Delaney upgraded Amphenol to Buy and raised his price target for the shares to $108 from $95. The company's "best in class" execution and "diverse" end markets position it well in a tougher cyclical environment, Delaney tells investors in a research note.
SYF Synchrony
$26.55

0.27 (1.03%)

01/03/19
SPHN
01/03/19
UPGRADE
Target $26
SPHN
Equal Weight
Synchrony upgraded to Equal Weight from Underweight at Stephens
Stephens analyst Vincent Caintic upgraded Synchrony to Equal Weight from Underweight as he sees worries about account losses, declining NIM and settlement costs as all built into the stock's recently "compressed" price. However, he also noted that his 2020 EPS estimate incorporates a "much smaller" portfolio than consensus, due to account loss expectations. Caintic maintains his $26 price target on Synchrony shares, adding that he sees Synchrony continuing to face top-line pressure through 2022.
11/02/18
SPHN
11/02/18
DOWNGRADE
Target $26
SPHN
Underweight
Synchrony downgraded to Underweight from Equal Weight at Stephens
Stephens analyst Vincent Caintic downgraded Synchrony (SYF) to Underweight from Equal Weight, citing the negative implications he sees from the lawsuit against the company from Walmart (WMT). Beyond the potential for over $800M in damages, the suit implies the Sam's Club account is lost, the Amazon (AMZN) account is "in jeopardy," and other retailers can be expected to "take a hard look" at their own relationships with Synchrony, Caintic believes. He lowered his price target on Synchrony shares to $26 from $32.
10/02/18
JPMS
10/02/18
UPGRADE
Target $89
JPMS
Overweight
Discover upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Shane upgraded Discover Financial (DFS) to Overweight and raised his price target for the shares to $89 from $81. The company appears on track to execute a "soft landing" as loan growth stabilizes, Shane tells investors in a research note. The analyst says credit has outperformed expectations while multiples in the Credit Card space have compressed. This creates a more attractive opportunity for investment, according to Shane. He also raised his price target for Overweight-rated Capital One (COF) to $113 from $109 and for Neutral-rated American Express (AXP) to $115 from $105.
09/26/18
09/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cabot Oil & Gas (COG) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Devin McDermott saying U.S. natural gas should soon enter a new cycle of structural oversupply and stagnating demand. 2. Manhattan Associates (MANH) downgraded to Hold from Buy at SunTrust with analyst Terry Tillman saying while there was no change in his view of the company's fundamentals, the risk reward on the stock is much more balanced after it "outperformed significantly" since the last earnings report. 3. Lam Research (LRCX) downgraded to Neutral from Buy at UBS. 4. Paycom (PAYC) and Synchrony (SYF) were downgraded to Neutral from Buy at BofA/Merrill. 5. DowDuPont (DWDP) downgraded to Neutral from Buy at Nomura Instinet with analyst Aleksey Yefremov citing his commodity models based on recent changes in chemical prices and margins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WAT Waters
$203.52

-3.315 (-1.60%)

01/02/19
NEED
01/02/19
INITIATION
Target $177
NEED
Hold
Waters initiated with a Hold at Needham
Needham analyst Stephen Unger started Waters Corp. with a Hold rating and $177 fair value estimate.
01/03/19
BOFA
01/03/19
UPGRADE
BOFA
Neutral
Waters upgraded to Neutral from Underperform at BofA/Merrill
01/03/19
BOFA
01/03/19
UPGRADE
BOFA
Neutral
Waters upgraded to Neutral on buyback support at BofA/Merrill
As previously reported, BofA/Merrill upgraded Waters to do to Neutral from Underperform and raised its price target to $193 from $180. Analyst Derik de Bruin raised Waters estimates citing an aggressive share buyback program that offers earnings support.
01/03/19
01/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Neutral from Reduce at New Street with analyst Pierre Ferragu saying the news is as bad as can be and the thesis is "fully played out." 2. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying revenue growth should continue in the 15-20% range for 2-3 years which coupled with abating margin pressure and share buybacks, should lead to over 15% earnings growth between 2020-2022. 3. First Solar (FSLR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying solar stocks underperformed in 2018 as tariffs, China policy and oversupply drove a cyclical correction. 4. Stryker (SYK) upgraded to Outperform at Evercore ISI with analyst Ross Muken saying 2019 guidance has been de-risked following management commentary and said recent macro survey work suggests 7% organic growth is achievable. 5. Waters (WAT) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin citing an aggressive share buyback program that offers earnings support. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

IFF

International Flavors

$122.54

-0.98 (-0.79%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
International Flavors rating change at Goldman Sachs »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

QRVO

Qorvo

$69.15

-0.93 (-1.33%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Qorvo rating change at Goldman Sachs »

Qorvo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ATI

Allegheny Technologies

$26.02

0.065 (0.25%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Allegheny Technologies rating change at Goldman Sachs »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$4.98

0.17 (3.53%)

21:33
03/20/19
03/20
21:33
03/20/19
21:33
Upgrade
Internap rating change at Wells Fargo »

Internap upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$108.62

-1.79 (-1.62%)

, CAG

Conagra Brands

$22.91

0.095 (0.42%)

20:25
03/20/19
03/20
20:25
03/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.62

-1.79 (-1.62%)

CAG

Conagra Brands

$22.91

0.095 (0.42%)

CMC

Commercial Metals

$16.06

-0.06 (-0.37%)

GIII

G-III Apparel

$35.09

-0.475 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

HYMTF

Hyundai Motor

$0.00

(0.00%)

19:51
03/20/19
03/20
19:51
03/20/19
19:51
Periodicals
Hyundai shareholders to vote on Elliott Management dividend demand, Reuters says »

Hyundai Motor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVBF

CVB Financial

$21.12

-0.53 (-2.45%)

19:45
03/20/19
03/20
19:45
03/20/19
19:45
Hot Stocks
CVB Financial raises quarterly dividend to 18c from 14c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$57.84

0.345 (0.60%)

19:24
03/20/19
03/20
19:24
03/20/19
19:24
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

Kaman is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

VALE

Vale

$13.49

-0.21 (-1.53%)

19:19
03/20/19
03/20
19:19
03/20/19
19:19
Hot Stocks
Vale suspends operations at Alegria mine in Mariana complex on preventive basis »

Vale S.A. informs that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

EQH

AXA Equitable

$20.84

-0.565 (-2.64%)

19:12
03/20/19
03/20
19:12
03/20/19
19:12
Syndicate
AXA Equitable 40M share Secondary priced at $20.50 »

JPMorgan, Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change at Goldman Sachs »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary at Tigress Financial »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change at Goldman Sachs »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CE

Celanese

$101.04

0.08 (0.08%)

18:02
03/20/19
03/20
18:02
03/20/19
18:02
Hot Stocks
Celanese increases acetyl intermeditates prices »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

17:58
03/20/19
03/20
17:58
03/20/19
17:58
Syndicate
Frontdoor 16.73M share Secondary priced at $30.00 »

JPMorgan and Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.